Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.

The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...

Bayer is a deep contrarian play, trading at less than 6x P/E, with potential for 100%+ upside if litigation risks subside.

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...